Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

INM vs NMTC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INM Captures Overall Composite Edge (35.6 SELL vs 45.5 HOLD), While NMTC Leads 4–2 on Growth & Valuation Pillars

INM Overall Winner 6-Pillar Tally: INM 2 – 4 NMTC Matrix Metrics: INM 3 – 4 NMTC

As of Nov 20, 2026, InMed Pharmaceuticals Inc. Common Shares (INM) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (35.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMTC wins 4–2 across the 6-pillar growth and valuation breakdown. INM trades at $15.56 (N/M Forward P/E, 0.0% operating margin) versus NMTC at $0.65 (N/M Forward P/E, -63.4% operating margin).

  • Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. INM 35.6/100 SELL), INM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.4% operating margin) and revenue trajectory (-26.2% vs. +16.3% YoY).
  • Technical & Structure Timing Caution: INM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 99.3); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INM vs NMTC
INM NASDAQ Head-to-Head Winner
InMed Pharmaceuticals Inc. Common Shares
Pharmaceutical Preparations
$15.56
+17.79% 1D
Market Cap $7.3M
TTM Revenue $4.9M
Forward P/E N/M
Beta / 30D Vol -20.85β · 2208% Vol
Unified Composite Score
35.6 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (37.6% over 20 days), RSI 99
RSI-14: 99.3 · SMA20: $2.77 · SMA50: $1.91
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03

6-Pillar Scorecard Institutional Category Breakdown (INM 2 – 4 NMTC)

Columns: Metric · INM · NMTC
1. Valuation Multiples NMTC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.5x 0.3x
2. Growth & Scale NMTC
Revenue Growth (YoY) -26.2% +16.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.9M $12M
Market Cap $7.3M $6.1M
3. Profitability & Quality INM
Gross Margin 34.5% 23.0%
Operating Margin 0.0% -63.4%
Net Profit Margin 0.0% -59.7%
Return on Equity (ROE) -222.1% -124.7%
4. Balance Sheet & Cash Flow NMTC
Cash Generation (TTM) -$7.5M -$7.6M
Cash Flow Margin N/A -60.7%
Net Cash / Leverage $4.7M Net Cash $2.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NMTC
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat INM
OpEx & R&D Intensity 34.5% of Rev ($1.7M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INM (3) vs NMTC (4)
Institutional Metric INM NMTC Criterion Row Edge
Market Capitalization
Scale
$7.3M $6.1M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-26.2% +16.3% Higher Growth NMTC
Operating Margin (TTM)
Profitability
0.0% -63.4% Higher Margin INM
Net Profit Margin
Profitability
0.0% -59.7% Higher Margin INM
Return on Equity (ROE)
Capital Efficiency
-222.1% -124.7% Higher ROE NMTC
52-Week Range Position
Momentum
94% ($1–$16) 2% ($1–$5) Stronger Trend INM
Beta / 30D Volatility
Risk Regime
-20.85β · 2208% Vol 1.55β · 105% Vol Lower Realized Risk NMTC
Unified Institutional Score
Composite Signal
35.6 / 100 (SELL) 45.5 / 100 (HOLD) Higher Composite NMTC
Trailing 12M Revenue (USD)
Operating Scale
$4.9M $12M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.5% 23.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.5x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.5M ($4.7M Net Cash) -$7.6M ($2.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INM +1088.53 pp
INM: +1069.92% · NMTC: -18.61%
3M Horizon INM +1047.2 pp
INM: +1003.55% · NMTC: -43.65%
6M Horizon INM +2375.38 pp
INM: +2293.85% · NMTC: -81.53%
1Y Horizon INM +1125.54 pp
INM: +1165.04% · NMTC: +39.5%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period INM Revenue NMTC Revenue INM Op. Margin NMTC Op. Margin Margin Leader
FY2012 N/A $0M N/A -1491.1% NMTC
FY2013 N/A $0M N/A -2009.0% NMTC
FY2014 N/A $0M N/A -4646.1% NMTC
FY2021 $0M $0M -535.9% -5735.9% INM
FY2022 $0M $0M -1361.9% -5860.2% INM
FY2023 $0M $0M -192.2% -612.3% INM
FY2024 $0M $0M -166.9% -344.3% INM
FY2025 $0M $10M -165.1% -46.5% NMTC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact INM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $7.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment 34.5% of Rev ($1.7M)
90D Engineering Disclosures 0 Published
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ INM vs NMTC Key Questions & Quantitative Answers

As of Nov 20, 2026, InMed Pharmaceuticals Inc. Common Shares (INM) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (35.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMTC wins 4–2 across the 6-pillar growth and valuation breakdown. INM trades at $15.56 (N/M Forward P/E, 0.0% operating margin) versus NMTC at $0.65 (N/M Forward P/E, -63.4% operating margin). Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. INM 35.6/100 SELL), INM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.4% operating margin) and revenue trajectory (-26.2% vs. +16.3% YoY). Technical & Structure Timing Caution: INM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 99.3); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMTC leads the Growth & Scale pillar: INM posts -26.2% YoY revenue growth and +0.0% YoY earnings growth on $4.9M TTM revenue (34.5% gross margin, 0.0% operating margin), compared with NMTC at +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), INM cumulative revenue shifted N/A while NMTC shifted N/A. In operating R&D and SG&A reinvestment, INM deploys 34.5% of Rev ($1.7M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMTC.

NMTC screens cheaper on headline valuation multiples. INM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (unreported FCF margin), whereas NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INM (-222.1% ROE) versus NMTC (-124.7% ROE) capital efficiency.

In options market volatility and institutional positioning, INM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.85β · 2208% Vol realized risk). By comparison, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.